Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization

Core Insights - Tevogen Bio Holdings Inc. has signed a non-exclusive, non-binding Letter of Intent to evaluate a potential transaction with a global Contract Research Organization (CRO), which could enhance its clinical development capabilities and transition the company into a revenue-generating healthcare enterprise [1][2] Company Overview - Tevogen is a healthcare enterprise focused on affordability, efficiency, and scientific rigor, utilizing artificial intelligence and precision T cell therapy platforms to develop advanced therapies across various therapeutic areas [4] - The company’s lead initiative, Tevogen Bio, has completed a proof-of-concept clinical trial demonstrating the potential of its genetically unmodified allogeneic T cells, with a pipeline that includes virology, oncology, and neurology [5] Strategic Initiatives - Tevogen is exploring additional transactions related to life sciences, including domestic generics, biosimilars, medical devices, and innovative insurance solutions, reflecting its mission to advance sustainable innovation and improve patient access [3][7] Technology and Innovation - Tevogen.AI aims to transform drug development by accelerating target detection and optimizing clinical trial design through proprietary predictive technologies, leveraging cloud and data services from major technology providers [6]